Hyperpolarised xenon-129 diffusion-weighted magnetic resonance imaging for assessing lung microstructure in

James A Eaden1,2, Nicholas D Weatherley1,2, Ho-Fung Chan1

  • 1POLARIS, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.

ERJ Open Research
|August 31, 2023
PubMed
Abstract

Insights

Hyperpolarized 129-xenon (129Xe) diffusion-weighted MRI detects early microstructural changes in idiopathic pulmonary fibrosis (IPF) progression within 12 months. This imaging technique shows promise for monitoring IPF, especially as new treatments emerge.

Area of Science:

  • Pulmonary Medicine
  • Radiology
  • Medical Imaging

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease.
  • Hyperpolarized 129-xenon (129Xe) MRI offers a non-ionizing method to assess lung microstructure and function.
  • Diffusion-weighted (DW)-MRI with hyperpolarized gases can reveal insights into lung tissue changes.

Purpose of the Study:

  • To compare 129Xe DW-MRI measurements with standard pulmonary function tests (PFTs) in IPF patients.
  • To evaluate the ability of 129Xe DW-MRI to detect early signs of disease progression in newly diagnosed IPF.
  • To assess the utility of 129Xe DW-MRI in monitoring IPF progression over 12 months.

Main Methods:

  • A prospective, single-centre observational study involving patients with newly diagnosed IPF.
  • Hyperpolarized 129Xe DW-MRI was performed at 1.5T.
  • Pulmonary function tests (PFTs) were conducted concurrently with MRI scans.

Main Results:

  • Global 129Xe apparent diffusion coefficient (ADC) significantly increased from baseline to 12 months (p=0.044).
  • 129Xe ADC also increased in the lower lung zones (p=0.027), alongside an increased mean acinar dimension (p=0.033).
  • 129Xe DW-MRI measurements showed strong correlations with diffusing capacity for carbon monoxide (DLCO) and transfer coefficient (KCO).

Conclusions:

  • 129Xe DW-MRI measurements are sensitive to early microstructural disease progression in IPF at 12 months.
  • The technique detected changes not evident in PFTs over the same period.
  • Quantifying subtle changes with 129Xe DW-MRI may be valuable for monitoring IPF, especially with emerging therapies.